Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2011 1
2015 1
2018 1
2019 2
2020 1
2021 1
2022 1
2023 1
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
Cervo A, Russo A, Di Carlo D, De Vito A, Fabeni L, D'Anna S, Duca L, Colpani A, Fois M, Zauli B, Mancarella G, Carraro A, Bezenchek A, Cozzi-Lepri A, Santoro MM; ARCA Study Group. Cervo A, et al. J Glob Antimicrob Resist. 2023 Sep;34:141-144. doi: 10.1016/j.jgar.2023.07.006. Epub 2023 Jul 13. J Glob Antimicrob Resist. 2023. PMID: 37453495 Free article.
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
Stella G, Volpicelli L, Carlo DD, Vicenti I, Celani L, Maggiolo F, Callegaro AP, Gennari W, Francisci D, Lombardi F, Piermatteo L, Bezenchek A, Micheli V, Rossetti B, Santoro MM; ARCA Study Group. Stella G, et al. Int J Antimicrob Agents. 2022 Sep;60(3):106636. doi: 10.1016/j.ijantimicag.2022.106636. Epub 2022 Jul 9. Int J Antimicrob Agents. 2022. PMID: 35820534
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.
Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, Di Biagio A; ARCA Study Group. Ungaro R, et al. Clin Microbiol Infect. 2019 Nov;25(11):1443-1446. doi: 10.1016/j.cmi.2019.07.004. Epub 2019 Jul 25. Clin Microbiol Infect. 2019. PMID: 31352080 Free article. No abstract available.
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
Lombardi F, Giacomelli A, Armenia D, Lai A, Dusina A, Bezenchek A, Timelli L, Saladini F, Vichi F, Corsi P, Colao G, Bruzzone B, Gagliardini R, Callegaro A, Castagna A, Santoro MM; ARCA Study Group. Lombardi F, et al. Int J Antimicrob Agents. 2021 Feb;57(2):106252. doi: 10.1016/j.ijantimicag.2020.106252. Epub 2020 Nov 28. Int J Antimicrob Agents. 2021. PMID: 33259914 Free article.
Correction: Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).
Hendrickx N, Mentré F, Traschütz A, Gagnon C, Schüle R; ARCA Study Group; EVIDENCE-R. N. D. consortium; Synofzik M, Comets E. Hendrickx N, et al. AAPS J. 2024 May 24;26(4):62. doi: 10.1208/s12248-024-00932-8. AAPS J. 2024. PMID: 38789847 No abstract available.
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G, Borghi V, Callegaro AP, Bruzzone B, Saladini F, Maggiolo F, Maffongelli G, Andreoni M, De Gennaro M, Gianotti N, Bagnarelli P, Vergori A, Antinori A, Zazzi M, Zaccarelli M; ARCA Study Group. Sterrantino G, et al. Int J Antimicrob Agents. 2019 Apr;53(4):515-519. doi: 10.1016/j.ijantimicag.2019.02.007. Epub 2019 Feb 12. Int J Antimicrob Agents. 2019. PMID: 30769200
14 results